Phage

© GettyImages/iLexx

BARDA and Locus in tie-up to tackle UTIs with phages

By Jane Byrne

Locus Biosciences has signed a contract with BARDA to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage) that targets E. coli bacteria causing recurrent urinary tract infections (UTIs).

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers